Egypt’s Hepatitis C Program: A Model for Africa’s Health Initiatives

By Crystal Lubbe

December 12, 2024

The article from the Africa CDC website, titled “Egypt’s Hepatitis Programme Becomes a Model for African Countries,” highlights Egypt’s successful hepatitis C elimination program, which serves as a benchmark for other African countries. By implementing the “100 Million Healthier Lives” campaign, Egypt has achieved Gold-tier certification for its progress toward eliminating hepatitis C, as recognised by the World Health Organization (WHO). This remarkable achievement showcases how effective public health initiatives can lead to significant health improvements across the continent.

Egypt’s Hepatitis C Elimination Program

Egypt Hepatitis C Program has benefited its citizens and set a powerful example for other African nations. Notably, the country has made significant strides in training and capacity building.

Training and Capacity Building

The Africa CDC, in collaboration with Egypt’s Ministry of Health and Population, has implemented training programs for experts from various African Union member states. These programs are designed to equip participants with the necessary skills to launch “screen-and-treat” programs for hepatitis C. To date, 26 members have been trained, with an additional cohort of 31 participants from multiple African countries completing their training in November 2024.

Regional Collaboration and Support

Moreover, Egypt plays a pivotal role by providing technical support, screening software, and free treatment for one million people in 14 African nations. This collaborative effort aligns with WHO screening and treatment guidelines.

Best Practices and Challenges

The training includes lectures, field trips, and discussions on best practices and challenges in hepatitis elimination. Participants visit hospitals, healthcare settings, and pharmaceutical companies to understand Egypt’s comprehensive strategy.

Africa CDC’s Role

The Africa CDC is actively supporting African nations by funding seroprevalence surveys, providing necessary kits and drugs, and training health workers. For example, Madagascar is currently undergoing a capacity and readiness assessment for viral hepatitis elimination, as part of the support provided by the Africa CDC.

South-South Cooperation

The initiative promotes South-South cooperation, encouraging shared learning and collaboration to improve public health outcomes continent-wide. This approach is a cornerstone of Egypt’s hepatitis C elimination successes and its potential replicability in other African countries.

Action Plans and Future Initiatives

Country representatives create action plans to apply training and identify needed support from Africa CDC and Egypt. For example, Cameroon is poised to launch a Triple elimination strategy, guided by the training and support it has received.

Conclusion

Egypt Hepatitis C Program stands as a model for other African countries. Notably thanks to its comprehensive approach, innovative financing, and political commitment. The program’s achievements signal a promising pathway toward the global goal of eliminating viral hepatitis by 2030. With continued regional collaboration and strong action plans, the impact of Egypt’s efforts will undoubtedly resonate across the continent.

Reference url

Recent Posts

health technology assessment Oman
            

Implementing Health Technology Assessment in Oman

🚀 Is Oman ready to revolutionize its healthcare decision-making?

A new roadmap for health technology assessment (HTA) is set to enhance evidence-based practices, streamline resource allocation, and address the challenges of rising healthcare costs. This phased strategy not only focuses on immediate capacity-building but also envisions comprehensive integration over the next decade!

Dive into the article to explore Oman’s strategic approach to improving healthcare delivery and its implications for the region.

#SyenzaNews #HealthTechnology #HealthcarePolicy #Innovation

TAVR asymptomatic approval
         

TAVR Asymptomatic Approval: A New Era for Early Intervention in Aortic Stenosis

🚨 Is it time to rethink how we treat asymptomatic severe aortic stenosis?

The FDA’s recent approval of the Edwards Lifesciences Sapien 3 TAVR devices could revolutionize cardiac care, allowing earlier intervention that dramatically reduces severe outcomes. This new approach, supported by the groundbreaking EARLY TAVR trial, challenges traditional “watchful waiting” strategies and emphasizes the need for proactive treatment to enhance patient outcomes and potentially lower healthcare costs.

Curious to learn more about this pivotal shift in medical practice? Dive into the full article for in-depth insights!

#SyenzaNews #HealthcareInnovation #HealthEconomics #MarketAccess

CVS Wegovy pricing deal
    

Wegovy CVS Deal: Hybrid Market Access Strategy Insights

💡 Are you curious about how pricing strategies can reshape access to vital medications?

The recent CVS-Novo Nordisk agreement for Wegovy, set at an astonishingly low cash price of $499, is poised to enhance accessibility for uninsured patients, while also influencing market dynamics and competition among obesity therapies. This strategic move highlights the power of pharmacy benefit managers in driving patient-oriented solutions.

Explore the full analysis and its implications for patient access and industry competition [here](https://www.biopharmadive.com/news/cvs-novo-nordisk-wegovy-deal/746887/).

#SyenzaNews #pharmaceuticals #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.